A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with Tocilizumab 8mg/kg intravenously versus Adalimumab 40mg subcutaneously in patients with rheumatoid arthritis

Principal Investigator(s)

Dennis A. Jerdan, M.D.

C. Michael Franklin, M.D. (Sub-Investigator)

Charles H. Pritchard, M.D. (Sub-Investigator)

Mark Lopatin, M.D. (Sub-Investigator)

David J. Chesner, D.O. (Sub-Investigator)

Elana R. Eisner, M.D. (Sub-Investigator)

Marguerite L. McGarvey, M.D. (Sub-Investigator)

Clinical Trial Categories

• Arthritis

Contact

Sue Falbo at 215-657-9977